Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 4,018.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 469,557 shares of the company's stock after purchasing an additional 458,157 shares during the period. Janus Henderson Group PLC owned about 1.04% of Apogee Therapeutics worth $27,586,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Arizona State Retirement System grew its stake in Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company's stock worth $236,000 after purchasing an additional 258 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after buying an additional 285 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Apogee Therapeutics during the third quarter valued at $71,000. Principal Financial Group Inc. raised its holdings in shares of Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company's stock valued at $253,000 after acquiring an additional 1,340 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Apogee Therapeutics by 25.7% in the third quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company's stock worth $517,000 after acquiring an additional 1,800 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Stock Up 6.0 %

Shares of Apogee Therapeutics stock traded up $2.81 during trading on Friday, reaching $49.97. The company's stock had a trading volume of 438,600 shares, compared to its average volume of 504,758. Apogee Therapeutics, Inc. has a 1-year low of $19.91 and a 1-year high of $72.29. The company has a 50-day simple moving average of $52.41 and a two-hundred day simple moving average of $48.31.

Insider Buying and Selling

In other news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the sale, the insider now directly owns 274,128 shares in the company, valued at $15,422,441.28. This represents a 2.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the business's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total transaction of $2,249,200.00. Following the transaction, the chief executive officer now owns 1,354,487 shares in the company, valued at $76,162,804.01. The trade was a 2.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 89,995 shares of company stock worth $4,912,264. Insiders own 36.10% of the company's stock.

Analyst Upgrades and Downgrades

APGE has been the subject of several recent research reports. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Guggenheim restated a "buy" rating and set a $110.00 target price (up previously from $95.00) on shares of Apogee Therapeutics in a report on Tuesday. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 target price on the stock. Finally, Wedbush upped their price objective on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an "outperform" rating in a research note on Monday, December 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $83.88.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.